Physician profile
Daniel Karel
NPI 1962999896
$4,086.67
in general payments reported to CMS, 2019-2025
28 companies · $856 in 2025
The $856 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,022 · 2023: $1,133 · 2024: $1,076 · 2025: $856.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,065.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,064.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $404.64 | 2023-2025 | |
| Abbvie INC. | $287.71 | 2022-2025 | |
| Seagen INC. | $245.79 | 2022 | |
| Sobi, INC | $244.09 | 2022-2023 | |
| Alexion Pharmaceuticals, INC. | $224.48 | 2023 | Ultomiris |
| Celgene Corporation | $213.16 | 2023-2025 | Breyanzi, Pomalyst, Reblozyl |
| Pfizer INC. | $211.49 | 2022-2024 | |
| Foundation Medicine, INC. | $168.96 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $160.76 | 2022 | |
| Daiichi Sankyo INC. | $159.04 | 2024-2025 | Enhertu, Injectafer |
| Janssen Biotech, INC. | $156.58 | 2024-2025 | Darzalex, Tecvayli, Talvey |
| Teleflex LLC | $142.01 | 2024 | Arrow |
| Gilead Sciences, INC. | $136.50 | 2024 | Trodelvy |
| Apellis Pharmaceuticals, INC. | $136.16 | 2023 | Empaveli |
| Genentech USA, INC. | $132.90 | 2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $126.95 | 2024 | Monjuvi |
| Beigene USA, INC. | $125.00 | 2023 | Brukinsa |
| Beone Medicines USA, INC. | $123.50 | 2025 | Brukinsa |
| Blueprint Medicines Corporation | $121.83 | 2024 | Ayvakit |
| E.R. Squibb & Sons, L.L.C. | $114.33 | 2023 | Pomalyst |
| Syndax Pharmaceuticals, INC. | $113.70 | 2025 | Revuforj |
| Rigel Pharmaceuticals, INC. | $99.02 | 2023 | Rezlidhia, Tavalisse |
| Novartis Pharmaceuticals Corporation | $73.99 | 2025 | |
| Merck Sharp & Dohme LLC | $43.15 | 2022-2025 | Lynparza, Keytruda |
| Stemline Therapeutics INC. | $41.07 | 2024 | Orserdu |
| Pharmacyclics LLC, An Abbvie Company | $32.22 | 2022 | |
| Janssen Scientific Affairs, LLC | $27.99 | 2024 | |
| Lilly USA, LLC | $19.65 | 2024 | Retevmo, Jaypirca, Verzenio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Karel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.